PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30721106-0	2019	Detection of hemophagocytic extremely multinucleated giant plasma cells after rituximab/low-dose lenalidomide treatment in CD20+ multiple myeloma.	Lenalidomide	97-109	keratin 20	Homo sapiens	123-127	
31406628-3	2019	Furthermore, we investigated if lenalidomide, a potential sensitizer to anti-CD20 treatment, could prevent an inhibitory effect of ibrutinib.	Lenalidomide	32-44	keratin 20	Homo sapiens	77-81	
26002964-7	2015	Of particular clinical importance, lenalidomide also allowed NK cells to be activated by lower doses of rituximab, an anti-CD20 monoclonal antibody (mAb) widely used to treat B-cell malignancies.	Lenalidomide	35-47	keratin 20	Homo sapiens	123-127	
27980307-4	2016	Furthermore, some targeting drugs, such as lenalidomide, bortezomib and ibrutinib, directly or indirectly affect CD20 protein expression.	Lenalidomide	43-55	keratin 20	Homo sapiens	113-117	
25632047-1	2015	PURPOSE: Lenalidomide, an immunomodulatory agent that enhances antibody-dependent cell-mediated cytotoxicity, has the potential to synergize with rituximab, an anti-CD20 mAb.	Lenalidomide	9-21	keratin 20	Homo sapiens	165-169	
25547653-0	2015	Lenalidomide differently modulates CD20 antigen surface expression on chronic lymphocytic leukemia B-cells.	Lenalidomide	0-12	keratin 20	Homo sapiens	35-39	
18772452-0	2008	Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.	Lenalidomide	0-12	keratin 20	Homo sapiens	32-36	
22171982-3	2012	Lenalidomide, an immunomodulator, is clinically effective in CLL and can enhance the anti-CLL effects of CD20 targeting monoclonal antibody, rituximab.	Lenalidomide	0-12	keratin 20	Homo sapiens	105-109	
25313353-9	2014	Lenalidomide also upregulated CD20 expression on leukemia cells and, accordingly, it had a synergistic effect with rituximab on promoting antibody-dependent cell-mediated cytotoxicity against primary leukemia cells.	Lenalidomide	0-12	keratin 20	Homo sapiens	30-34	
18772452-2	2008	The anti-CD20 antibody rituximab is active in CLL and represents a rational agent to combine with lenalidomide.	Lenalidomide	98-110	keratin 20	Homo sapiens	9-13	
18772452-4	2008	In contrast to previous reports using CD20-positive lymphoma cell lines, lenalidomide down-regulated CD20 surface antigen expression in CLL patient cells via enhanced internalization, without influencing transcription.	Lenalidomide	73-85	keratin 20	Homo sapiens	101-105	
18772452-6	2008	In addition, CD20 surface antigen down-modulation by lenalidomide in CLL was accompanied by diminished rituximab-mediated apoptosis and ADCC.	Lenalidomide	53-65	keratin 20	Homo sapiens	13-17	
18772452-8	2008	In addition, they suggest that lenalidomide therapy might be useful to enhance targeted delivery of RNAi-based therapies using CD20 immunoliposomes in B-cell malignancies.	Lenalidomide	31-43	keratin 20	Homo sapiens	127-131	
18628480-0	2008	lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.	Lenalidomide	0-12	keratin 20	Homo sapiens	126-130